Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

NCT01283789 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT01283789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01283789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2011
Completion date
April 30, 2017
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer